Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
Completed
Novartis
Phase 3
1969-12-31
This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled,
36-month study comparing the length of time of progression from mild cognitive impairment
(MCI) to a clinical diagnosis of Alzheimer's disease (AD) in subjects taking Exelon vs.
placebo. Exelon is currently under review with the U.S. Food and Drug Administration as a
treatment for Alzheimer's disease. The drug has been cleared for marketing in more than 40
countries for Alzheimer's disease to date, including all 15 member states of the European
Union, New Zealand, Argentina, Brazil and Mexico.
Each subject with MCI will be randomly assigned to treatment with either Exelon or placebo.
Subjects assigned to Exelon will receive 1.5 to 6.0 mg bid (twice daily) (3.0 to 12 mg/day)
for the majority of the study. At every regular visit scheduled every three months, patients
will be given basic efficacy and safety assessments. These assessments will include
evaluation of adverse events, vital signs, activities of daily living, and clinical staging
scales to determine if the subject may have converted to dementia.
Electrophysiologic Measures of Treatment Response in Alzheimer Disease
Completed
US Department of Veterans Affairs
Phase 4
1998-10-01
The main purpose of this study is to determine the electrophysiological effects of
cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer
disease. The attempt will be to locate electrophysiological markers and predictors of
cognitive and clinical treatment response.
Electrophysiologic Measures of Treatment Response in Alzheimer Disease
Completed
VA Office of Research and Development
Phase 4
1998-10-01
The main purpose of this study is to determine the electrophysiological effects of
cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer
disease. The attempt will be to locate electrophysiological markers and predictors of
cognitive and clinical treatment response.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
